Background: Juvenile idiopathic arthritis (JIA) consists of a heterogeneous group of disorders
with, for the most part, an unknown immunopathogenesis. Although onset and disease …

Objective: We undertook an observational study to obtain a complete overview of the long-term
effectiveness and safety of etanercept in patients with different juvenile idiopathic arthritis …

Background Analysis of myeloid-related protein 8 and 14 complex (MRP8/14) serum
concentrations is a potential new tool to support the diagnosis of systemic-onset juvenile idiopathic …

Context Since the introduction of biologic therapies, the pharmacological treatment approach
for juvenile idiopathic arthritis (JIA) has changed substantially, with achievement of inactive …

Objective: To assess the effect of measles, mumps and rubella (MMR) vaccination on
disease activity in children with juvenile idiopathic arthritis (JIA). Methods: A retrospective …

Introduction Approximately 30 % of juvenile idiopathic arthritis (JIA) patients fail to respond
to anti-TNF treatment. When clinical remission is induced, some patients relapse after …

Objective Objective evaluation of disease activity is challenging in patients with juvenile
dermatomyositis ( DM ) due to a lack of reliable biomarkers, but it is crucial to avoid both under‐ …

Background Treatment of juvenile idiopathic arthritis (JIA) has changed dramatically since
the introduction of biological agents in 1999. Objective To evaluate trends in prescription …

Objective To evaluate the effectiveness and safety of switching to a second or third biological
agent in juvenile idiopathic arthritis (JIA) after etanercept failure. Methods The Arthritis and …

Objective. To evaluate the effectiveness and safety of biological agents in children with
enthesitis-related arthritis (ERA). Methods. All patients with ERA in whom a biological agent was …